Drug Trial Radar · NCT01397539
Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Mar 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jun 2011
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jul 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and tolerability of a range of BIIB037 doses administered as single intravenous (IV) infusions in participants with mild to moderate Alzheimer's Disease (AD). Secondary objectives of this study in this study population are to assess the pharmacokinetics(PK) and to evaluate the immunogenicity of BIIB037 after single-dose administration.
Conditions
- Alzheimer's Disease
Interventions
BIIB037Drug
Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
PlaceboOther
Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Brain Matters Research
Delray Beach, Florida
Compass Research, LLC
Orlando, Florida
Insight Clinical Trials, LLC
Beachwood, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.